7 Results

People

  1. Hamlin
    Hamlin
  2. Horwitz
    Horwitz
  3. Sirotnak
    Sirotnak
  4. Moskowitz
    Moskowitz
  5. Portlock
    Portlock
  6. Zelenetz
    Zelenetz
  7. Sarasohn
    Sarasohn
  8. Fleisher
    Fleisher
  9. Neylon
    Neylon
  10. Noy
    Noy

Groups

  1. Center for Hematologic Malignancies (7)
  2. Department of Medicine (7)
  3. Hematologic Malignancies, Division of (7)
  4. Lymphoma (7)
  5. Population Sciences Research Program (7)
  6. Body Imaging Service (5)
  7. Radiology, Department of (5)
  8. Nursing (3)
  9. Biostatistics Service (2)
  10. Epidemiology and Biostatistics (2)
  1. "Paul Hamlin"
  2. "Francis Sirotnak"
Formats
  1. Meeting Abstract (4)
  2. Journal Article (3)
Groups
  1. Center for Hematologic Malignancies (7)
  2. Department of Medicine (7)
  3. Hematologic Malignancies, Division of (7)
  4. Lymphoma (7)
  5. Population Sciences Research Program (7)
  6. Body Imaging Service (5)

More Groups

People
  1. Francis Sirotnak (7)
  2. Paul Hamlin (7)
  3. Steven Horwitz (7)
  4. Andrew Zelenetz (6)
  5. Carol Portlock (6)
  6. Craig Moskowitz (6)

More People

Years
  1. 2009 (2)
  2. 2008 (1)
  3. 2007 (1)
  4. 2006 (2)
  5. 2005 (1)
Publications
  1. Blood (2)
  2. Annals of Oncology (1)
  3. British Journal of Haematology (1)
  4. Clinical Pharmacology & Therapeutics (1)
  5. EJC Supplements (1)
  6. Journal of Clinical Oncology (1)
Publishers
  1. American Society of Hematology (2)
  2. American Society of Clinical Oncology (1)
  3. John Wiley & Sons (1)
  4. Nature Publishing Group (1)
  5. Oxford University Press (1)
  6. Pergamon-Elsevier Science Ltd (1)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies
    Journal Article

    O'Connor, O. A.; Horwitz, S.; Hamlin, P.; Portlock, C.; Moskowitz, C. H.; Sarasohn, D.; Neylon, E.; Mastrella, J.; Hamelers, R.; Macgregor-Cortelli, B.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • A Population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-hodgkin's or hodgkin's lymphoma
    Journal Article

    Mould, D. R.; Sweeney, K.; Duffull, S. B.; Neylon, E.; Hamlin, P.; Horwitz, S.; Sirotnak, F.; Fleisher, M.; Saunders, M. E.; O'Connor, O. A.
    Clinical Pharmacology & Therapeutics (2009)

    Fulltext@MSK | Save
  • Pralatrexate (PDX) produces a high and durable complete response rate in patients with chemotherapy resistant T-cell lymphomas
    Meeting Abstract

    O'Connor, O. A.; Hamlin, P.; Moskowitz, C.; Portlock, C.; Sarasohn, D.; Dumitrescu, O.; Neylon, E.; Patterson, M.; Zelenetz, A.; Saunders, M.; more...
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma
    Journal Article

    O'Connor, O. A.; Hamlin, P. A.; Portlock, C.; Moskowitz, C. H.; Noy, A.; Straus, D. J.; Macgregor-Cortelli, B.; Neylon, E.; Sarasohn, D.; Dumetrescu, O.; more...
    British Journal of Haematology (2007)

    Fulltext@MSK | Save
  • Pralatrexate (PDX) produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-Cell lymphomas: Results of the MSKCC phase I/II experience
    Meeting Abstract

    O'Connor, O. A.; Hamlin, P. A.; Gerecitano, J.; Portlock, C. S.; Noy, A.; Moskowitz, C.; Straus, D. J.; Sarasohn, D.; Dumitrescu, O.; Pappanicholaou, J.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • Early phase experience with pralatrexate (10-propargyl-10-deazaaminopterin [PRX]), a novel antifolate with high affinity for the reduced folate carrier, in patients with chemotherapy refractory lymphoproliferative malignancies
    Meeting Abstract

    O'connor, O.; Hamlin, P.; Neylon, E.; Moskowitz, C.; Portlock, C.; Noy, A.; Sirotnak, F.; Zelenetz, A.; Mould, D.; Horwitz, S.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • Pralatrexate (10-propargyl-10-deazaaminopterin (PRX)), a novel antifolate, effects durable complete remissions (CR) in patients with a diversity of drug resistant T-cell lymphomas with minimal toxicity
    Meeting Abstract

    O'connor, O.; Hamlin, P. A.; Neylon, E.; Moskowitz, C.; Portlock, C. S.; Straus, D. J.; Noy, A.; Cortelli, B.; Zelenetz, A. D.; Fleisher, M.; more...
    Blood (2005)

    Fulltext@MSK | Save